Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study

Platelets

Volumn 27, Issue 8, 2016, Pages 796-804

  Bernlochner, Isabell ^a   Mayer, Katharina ^b   Orban, Martin ^c   Morath, Tanja ^b   Jaitner, Juliane ^a   Rössner, Lisa ^a   Gross, Lisa ^c   Laugwitz, Karl Ludwig ^a,d   Kastrati, Adnan ^b,d   Sibbing, Dirk ^c,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Clopidogrel; high on treatment platelet reactivity; prasugrel; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; HEPARIN; PRASUGREL; THROMBIN; TICAGRELOR; ADENOSINE; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; RISK FACTOR; THROMBOCYTE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

ADENOSINE; ADENOSINE DIPHOSPHATE; AGED; BLOOD PLATELETS; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84973598728     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537104.2016.1190007     Document Type: Article

References (42)

1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, et al. ESC/EACTS guidelines on myocardial revascularization:The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–2619.
2. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, Ten Berg J, Janssen P, Angiolillo DJ, et al. Bleeding and stent thrombosis on P2Y12-inhibitors:Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015;36:1762–1771.
3. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N., Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849–856.
4. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L., Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes:The PLATO (Platelet Inhibition and Patient Outcomes) platelet substudy. J Am Coll Cardiol 2010;56:1456–1462.
5. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:The onset/offset study. Circulation 2009;120:2577–2585.
6. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L., Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166–1173.
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.
8. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.
9. Montalescot G, Collet JP, Ecollan P, Bolognese L, Ten Berg J, Dudek D, Hamm C, Widimsky P, Tanguay JF, Goldstein P, et al. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for nstemi:The accoast-pci study. J Am Coll Cardiol 2014;64:2563–2571.
10. van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009;7:1556–1565.
11. Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ., The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096–1104.
12. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, et al. Comparison of prasugrel and ticagrelor loading doses in st-segment elevation myocardial infarction patients:Rapid (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601–1606.
13. Laine M, Frere C, Toesca R, Berbis J, Barnay P, Pansieri M, Michelet P, Bessereau J, Camilleri E, Ronsin O, et al. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. Thromb Haemost 2014;111:273–278.
14. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with st-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797–804.
15. Ibrahim K, Christoph M, Schmeinck S, Schmieder K, Steiding K, Schoener L, Pfluecke C, Quick S, Mues C, Jellinghaus S, et al. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 2014;85:649–656.
16. Angiolillo DJ, Curzen N, Gurbel P, Vaitkus P, Lipkin F, Li W, Jakubowski JA, Zettler M, Effron MB, Trenk D., Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease:Results of the SWAP-2 study (Switching Anti Platelet-2). J Am Coll Cardiol 2014;63:1500–1509.
17. Schulz S, Angiolillo DJ, Antoniucci D, Bernlochner I, Hamm C, Jaitner J, Laugwitz KL, Mayer K, von Merzljak B, Morath T, et al. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy-design and rationale of the intracoronary stenting and antithrombotic regimen:Rapid early action for coronary treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res 2014;7:91–100.
18. Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A., Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients:Initial evidence of a therapeutic window. J Am Coll Cardiol 2010;56:317–318.
19. Bernlochner I, Mayer K, Morath T, Orban M, Schulz S, Schomig A, Braun S, Kastrati A, Sibbing D., Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thromb Haemost 2013;109:517–524.
20. Sardella G, Calcagno S, Mancone M, Lucisano L, Pennacchi M, Stio RE, Placentino F, Di Roma A, Cavallo E, Palmirotta R, et al. Comparison of therapy with ticagrelor, prasugrel or high clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. Triplete reset trial. Int J Cardiol 2015;194:60–62.
21. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention:A pharmacodynamic study. J Am Coll Cardiol 2012;60:193–199.
22. Lhermusier T, Voisin S, Murat G, Mejean S, Garcia C, Bataille V, Lipinski MJ, Carrie D, Sie P., Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome:Comparative effects of prasugrel and ticagrelor on platelet reactivity. Int J Cardiol 2014;174:874–876.
23. Sibbing D, Kastrati A, Berger PB., Pre-treatment with P2Y12 inhibitors in ACS patients:Who, when, why, and which agent? Eur Heart J 2016;37:1284–1295.
24. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–933.
25. Tantry, US, Bonello L, Aradi D, Price, MJ, Jeong, YH, Angiolillo, DJ, Stone, GW, Curzen N, Geisler T, Ten Berg J, et al. Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–2273.
26. Penz SM, Bernlochner I, Toth O, Lorenz R, Calatzis A, Siess W., Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry. Thromb J 2010;8:9.
27. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009;119:2625–2632.
28. Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schomig A, von Beckerath N, Kastrati A., Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250–256.
29. Rollini F, Franchi F, Cho JR, DeGroat C, Bhatti M, Muniz-Lozano A, Singh K, Ferrante E, Wilson RE, Dunn EC, et al. A head-to-head pharmacodynamic comparison of prasugrel vs. Ticagrelor after switching from clopidogrel in patients with coronary artery disease:Results of a prospective randomized study. Eur Heart J 2016 Feb 3. DOI:ehv744. Epub ahead of print.
30. Alexopoulos D, Stavrou K, Koniari I, Gkizas V, Perperis A, Kontoprias K, Vogiatzi C, Bampouri T, Xanthopoulou I., Ticagrelor vs prasugrel one-month maintenance therapy:Impact on platelet reactivity and bleeding events. Thromb Haemost 2014;112:551–557.
31. Dillinger JG, Manzo Silberman S, Bal dit Sollier C, Amsallem M, Sideris G, Voicu S, Henry P, Drouet L. Ticagrelor effectiveness overestimated by VASP index:Platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests. Int J Cardiol 2014;176:557–559.
32. Lemesle G, Schurtz G, Bauters C, Hamon M., High on-treatment platelet reactivity with ticagrelor versus prasugrel:A systematic review and meta-analysis. J Thromb Haemost 2015;13:931–942.
33. Lhermusier T, Lipinski MJ, Tantry US, Escarcega RO, Baker N, Bliden KP, Magalhaes MA, Ota H, Tian W, Pendyala L, et al. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. Am J Cardiol 2015;115:716–723.
34. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014;63:872–877.
35. Linden MD, Barnard MR, Frelinger AL, Michelson AD, Przyklenk K., Effect of adenosine a2 receptor stimulation on platelet activation-aggregation:Differences between canine and human models. Thromb Res 2008;121:689–698.
36. Beitelshees AL, Voora D, Lewis JP., Personalized antiplatelet and anticoagulation therapy:Applications and significance of pharmacogenomics. Pharmgenomics Pers Med 2015;8:43–61.
37. Bernlochner I, Goedel A, Plischke C, Schupke S, Haller B, Schulz C, Mayer K, Morath T, Braun S, Schunkert H, et al. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. Eur Heart J 2015;36:3202–3210.
38. Mayer K, Orban M, Bernlochner I, Braun S, Schulz S, Gross L, Hadamitzky M, Schunkert H, Laugwitz KL, Massberg S, et al. Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets 2015;26:53–58.
39. Alexopoulos D, Xanthopoulou I, Storey RF, Bliden KP, Tantry US, Angiolillo DJ, Gurbel PA. Platelet reactivity during ticagrelor maintenance therapy:A patient-level data meta-analysis. Am Heart J 2014;168:530–536.
40. Aradi D, Kuliczkowski W, Atar D, Serebruany VL., Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Haemost 2012;107:338–345.
41. Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB., Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes:Results of the swap (switching anti platelet) study. J Am Coll Cardiol 2010;56:1017–1023.
42. Hibbert B, Maze R, Pourdjabbar A, Simard T, Ramirez FD, Moudgil R, Blondeau M, Labinaz M, Dick A, Glover C, et al. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention:The capital reload study. PLoS One 2014;9:e92078.